AARD Stock Analysis: Buy, Sell, or Hold?
AARD - Aardvark Therapeutics, Inc. Common Stock
$3.81
-0.16 (-4.03%)
▼
5d:
-4.51%
30d:
-27.7%
90d:
-32.45%
BUY
HIGH Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When AARD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AARD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: AARD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: AARD is currently trading at $3.81, which is considered oversold relative to its 30-day fair value range of $4.17 to $5.83.
Technical Outlook: Technically, AARD is in a strong downtrend. The price is currently testing key support at $3.70. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.44 (+305.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AARD is in a strong downtrend. The price is currently testing key support at $3.70. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.44 (+305.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.17 -
$5.83
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 305.4% below Wall St target ($15.44)
Trading Range Analysis
30-Day Trading Range
$4.17 -
$5.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.70
Resistance Level
$4.80
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.18
Wall Street Target
$15.44
(+305.4%)
Share & Embed Analysis
Last updated: June 03, 2026 5:57 PM ET
Data refreshes hourly during market hours. Next update: 6:57 PM
Data refreshes hourly during market hours. Next update: 6:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AARD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Nelson Sun
BUY
3000 shares
2025-12-11
Tien-Li Lee
BUY
7000 shares
2025-12-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 55 HOLD |
